ESR1 and breast carcinoma: To identify compounds that reduce viability of breast cancer cells bearing a mutated ERα, we performed a drug screen in ERα-MutA cells using a composite NKI drug library containing 2277 drugs targeting various pathways (Figure 1D; composition of the drug library can be found in Table S1).